Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-19
2006-12-19
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S081000, C514S411000, C544S142000, C548S432000, C423S316000
Reexamination Certificate
active
07151100
ABSTRACT:
The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4337760 (1982-07-01), Rubin
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-08-01), Dell
patent: 4542013 (1985-09-01), Keith et al.
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka et al.
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5780435 (1998-07-01), Garnick et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5968974 (1999-10-01), Kargman et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 6066741 (2000-05-01), Vigano et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 2002/0042375 (2002-04-01), Heimbrook et al.
patent: 2003/0004143 (2003-01-01), Prior et al.
patent: 2005/0239752 (2005-10-01), Carson et al.
patent: 1299577 (1992-04-01), None
patent: 2226 340 (1973-03-01), None
patent: 0289262 (1986-11-01), None
patent: 1436893 (1976-05-01), None
patent: 96/28148 (1996-09-01), None
patent: WO-9748391 (1997-12-01), None
patent: 98/09603 (1998-03-01), None
patent: 98/18490 (1998-05-01), None
patent: WO-98/40078 (1998-09-01), None
patent: 00/02555 (2000-01-01), None
patent: 00/13410 (2000-03-01), None
patent: WO-0106990 (2001-02-01), None
patent: WO-02/021225 (2002-01-01), None
patent: WO-0212188 (2002-02-01), None
Berendes, U.., et al. ,“Simultaneous Determination of the Phase II Metabolites of the Non Steriodal Anti-inflammatory Drug Etodolac in Human Urine”,Enantiomer, vol. 1, (1996),415-422.
Brenna, E.., et al. ,“New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron, 53, (1997),17769-17780.
Van Breemen, R..B. , et al. ,“Characterization of Oxygen-Linked Glucuronides by Laser Desorption Mass Spectrometry”,Biomed. Mass Spectrom., 11, Abstract Only, Chemical Abstracts, Abstract No. 101:106777c,(1984),278-283.
Venuti, M..C. ,et al. ,“Synthesis and Biological Evaluation of omega-(N,N,N-trialkylammonium)alkyl Esters and Thioesters of Carboxylic Acid Nonsteroidal Antiinflammatory Agents”,Pharm. Res., 6, Abstract Only, Chemical Abstracts, Abstract No. 112:111681y,(1989),867-873.
Abramson, S.B., et al., “The Mechanisms of Action of Nonsteroidal Antiinflammatory Drugs”,Arthritis&Rheumatism, 32 (1), pp. 1-9, (Jan. 1989).
Alexanian, R., et al., “The Treatment of Multiple Myeloma”,The New England Journal of Medicine, 330(7), pp. 484-489, (Feb. 17, 1994).
Barlogie, B., et al., “Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma”,Blood, 72(6), pp. 2015-2019, (Dec. 1988).
Bataille, R., et al., “Multiple Myeloma”,New England Journal of Medicine, 336(23), pp. 1657-1664, (Jun. 5, 1997).
Becker-Scharfenkamp, U., et al., “Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography, 621(2), pp. 199-207, (Nov. 24, 1993).
Bellosillo, B., et al., “Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood, 92(4), pp. 1406-1414, (Aug. 15, 1998).
Brocks, D.R., et al., “Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics, 26(4), pp. 259-274, (1994).
Carson, D.A., et al., “Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine”,Proc. Natl. Acad. Sci. USA, 89(7), pp. 2970-2974, (Apr. 1992).
Chinetti, G., et al., “Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages”,The Journal of Biological Chemistry, 273(40), pp. 25573-25580, (Oct. 2, 1998).
Cunningham, D., et al., “High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology, 12(4), pp. 764-768, (Apr. 1994).
Demerson, C.A., et al., “Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b] indole-1-acetic Acids”,Journal of Medicinal Chemistry, 19(3), pp. 391-395, (1976).
Demerson, C.A., et al., “Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem., 26(12), pp. 1778-1780, (Dec. 1983).
Drachenberg, D.F., et al., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology, 18(1), pp. 37-44, (Jan./Feb. 2000).
Duffy, C.P., et al., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology, 18(1), pp. 37-44, Jan./Feb. 2000).
Hahnfeld, L.E., et al., “Prostate Cancer”,The Medical Clinics of North America—The Aging Male Patient, 83(5), pp. 1231-1245, (Sep. 1999).
Harousseau, J.L., et al., “Double-Intensive Therapy in High-Risk Multiple Myeloma”,Blood, 79(11), pp. 2827-2833, (Jun. 1, 1992).
Krajewski, S., et al., “Detection of Multiple Antigens on Western Blots”,Analytical Biochemistry, 236(2), Article No. 0160, pp. 221-228, (May 1996).
Landis, S.H., et al., “Cancer Statistics, 1998”,CA Cancer J. Clin., 48(1), pp. 6-29, (1998).
Lee, D.H., et al., “Proteasome Inhibitors: Valuable New Tools For Cell Biologists”,Trends in Cell Biology, 8, pp. 397-403, (1998).
Lehmann, J.M., et al., “Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs”,The Journal of Biological Chemistry, 272(6), pp. 3406-3410, (Feb. 7, 1997).
Leoni, L.M., et al., “Induction of an Apoptotic Program in Cell-Free Extracts by 2-Chloro-2′-deoxyadenosine 5′-Triphosphate and Cytochrome C”,PNAS, USA, 95(16), pp. 9567-9571, (Aug. 4, 1998).
Lochmüller, C.H., et al., “Chromatographic Resolution of Enantiomers—Selective Review”,Journal of Chromatography, 113(3), pp. 283-302, (Oct. 22, 1975).
Martel, R.R., et al., “Anti-inflammatory and Analgesic Properties of Etodolic Acid in Rats”,Canadian Journal of Physiology and Pharmacology, 54(3), pp. 245-248, (Jun. 1976).
Mooney, P.T., et al., “Cell Pathways' Exisulind ‘Aptosyn’ Demonstrates Potential to Delay Hormone Therapy in Post-Prostatectomy Men at Risk of Prostate Cancer Recurrence”, http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html, 3 p., (May 2000).
Ricote, M., et al., “The Peroxisome Proliferator-Activated Receptor-γ is
Carson Dennis A.
Cottam Howard B.
Leoni Lorenzo M.
Schwegman Lundberg Woessner & Kluth P.A.
The Regents of the University of California
Ward Paul V.
Wilson James O.
LandOfFree
Indole compounds useful for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole compounds useful for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole compounds useful for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695565